From: Dawes, Grayson (OCEO)
To: Spinoza, Lina (OCEO)
Subject: Re: Strategy Memo FINAL
Thx, Lina. Excellent work. Will make my tweaks and send in the AM.
From: Spinoza, Lina (OCEO)
To: Dawes, Grayson (OCEO)
Subject: Strategy Memo FINAL
I finished the memo you wanted to send out with the Yinger report. I think I got all the points you wanted from the meeting earlier today, but I can do another pass if I missed something important.
From: Grayson Dawes, PHarmax Chief Executive Officer
To: PHarmax Executive Leadership Committee
Subject: Extraterrestrial Tech Transfer
We have definitive confirmation that the UAS Government and the United World Council will not take action to prevent the so-called “Technology Transfer” that the Aliens are going to initiate at 12:00 PM ET tomorrow. The impacts of this complete disregard for current intellectual property law will be immediate and negative. I have included with this memo a report from our consultants at The Yinger Group, a top market intelligence firm, that provides some scenarios and details about what all of this means means. We are far from the only industry or the only corporation that will be affected by this, but the impact on us is likely to be severe. Breakthroughs we have spent sizable amounts of Research and Development funding on could be disclosed, potentially eliminating trade secrets and patents we have fought long and hard to protect. Worse, many may be invalidated or rendered obsolete by the data from the tech transfer. We have little notion of what useful information will be included in the tech transfer, whether it be new antivirals, antibiotics, life extension technologies, viral therapies, synthetic organs, nano-level cellular reconstruction technologies, or something that proves even more of a game-changer. I have seen several white papers circulating that argue differences in biology between us and the Aliens should limit pharmaceutical or biomedical applications in the near-term, but I remain unconvinced of this argument no matter how much we wish we could believe it.
While we will take legal action against any who use data from the tech transfer to develop products similar to ours in order to delay and stop them from making it to market, that will do little to stop what will be an emerging black market for these technologies and medicines. We assume that this black market and underground economy may significantly affect existing profits as is already the case with illegal generic versions of our products. It is also likely that many scam artists will cut into our bottom line by promising miracle cures to diseases and other chronic health problems through these underground channels as well, likely claiming bogus Alien science supposedly obtained from the tech transfer. We are likely looking at several rough quarters or even years. As such, based upon the recommendations of the Yinger report, we should follow a two track strategy to ensure the survival of PHarmax in the face of these new challenges.
1. The first priority is to protect our product lines, be they in production or development stages. We have some initial confirmation that the data to be released through the feeds will be easily understood by individuals with some competence and knowledge of biomedical engineering and its related disciplines. This will likely mean that many startups will spring up virtually overnight.
1.a. As previously stated, we must take legal action when they infringe upon our existing intellectual property. We have a dedicated legal team in New York and DC from the law firm Knight, MacPherson, and Green on standby that have been briefed on the issue and are prepared to take appropriate action. We will continue the engagement with the Yinger Group to identify any products that sound similar to ours or produce similar effects. Cease and desist notices will go out early and often whenever we receive word that someone is developing something that could infringe. If they continue development, we will immediately file suit. This will jam up many of the startups and hopefully scare investors away from them as well. Most will likely be gone before they can launch products.
1.b. Media strategies will tag any startups in the industry as unreliable and inexperienced. Analysts friendly to PHarmax will make assertions in the feeds that such firms have connections to underground and black market sources and that their products cannot be trusted. PHarmax’s reputation and experience will be emphasized as a contrast.
2. Our next priority should be to take advantage of the opportunity to launch new product lines and exploit this unprecedented situation. Forecasters anticipate that demand for any Alien technology, including medical products, will be extremely high. Riots are anticipated as part of the distribution. PHarmax would forego significant profits to abstain from these business development opportunities.
2.a. In cases where the tech transfer discloses proprietary information not belonging to PHarmax but to PHarmax’s competitors, we should proceed immediately in testing, producing, and distributing products based upon this. Our legal will argue the unprecedented nature of this situation to proceed with infringement upon the intellectual property of our competitors. They will likely try the strategy outlined in 1.a. of cease and desist letters and suits against us, but we are not some startup that can be intimidated into bankruptcy by such actions. The reward outweighs the risk
2.b. Our legal team assures us that we can further utilize the unprecedented nature of this situation to explain why traditional testing and approval of all medical products should be expedited. Communications will stress the explosive growth of underground and black market distribution of these technologies and how dangerous they are as they have been subject to essentially no safety or testing. Correspondingly, it will be argued that it is irresponsible to constrain respectable and established companies with expertise with red tape while these unsafe drugs are being produced illegally with no regard for safety or testing. We already have several pieces of draft legislation that may gut the testing process for established firms who can obtain a waiver. Our lobbyists assure me that the waiver process will be constructed to benefit established companies with solid past performance and corporate experience over startups.
Many will view these developments as a simple positive. It is our job to make sure the consumer understands the complexity and unprecedented nature of this situation. We must make all efforts to educate the consumer that many untrusted and inexperienced sources and, frankly, outright frauds will exploit this situation to make profits and that they should trust the same firms with their healthcare and medical products that they always have. Together, we can weather this storm and retain our dominance in the industry as this chaotic situation unfolds.
Chief Executive Officer
PHarmax Biomedical Technologies, LLC